Details for Patent: 8,080,580
✉ Email this page to a colleague
Which drugs does patent 8,080,580 protect, and when does it expire?
Patent 8,080,580 protects SEGLUROMET, STEGLATRO, and STEGLUJAN, and is included in three NDAs.
This patent has sixty patent family members in forty-nine countries.
Summary for Patent: 8,080,580
| Title: | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| Abstract: | Compounds of Formula (I) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors). ##STR00001## |
| Inventor(s): | Mascitti; Vincent (Groton, CT), Collman; Benjamin M. (Ledyard, CT) |
| Assignee: | Pfizer Inc. (New York, NY) |
| Application Number: | 12/546,306 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,080,580 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,080,580
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd Sub Merck | SEGLUROMET | ertugliflozin; metformin hydrochloride | TABLET;ORAL | 209806-002 | Dec 19, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | ⤷ Sign Up | ||
| Msd Sub Merck | SEGLUROMET | ertugliflozin; metformin hydrochloride | TABLET;ORAL | 209806-001 | Dec 19, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | ⤷ Sign Up | ||
| Msd Sub Merck | SEGLUROMET | ertugliflozin; metformin hydrochloride | TABLET;ORAL | 209806-004 | Dec 19, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | ⤷ Sign Up | ||
| Msd Sub Merck | SEGLUROMET | ertugliflozin; metformin hydrochloride | TABLET;ORAL | 209806-003 | Dec 19, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | ⤷ Sign Up | ||
| Msd Sub Merck | STEGLATRO | ertugliflozin | TABLET;ORAL | 209803-001 | Dec 19, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | ⤷ Sign Up | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,080,580
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2334687 | ⤷ Sign Up | 122018000070 | Germany | ⤷ Sign Up |
| European Patent Office | 2334687 | ⤷ Sign Up | 300943 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2334687 | ⤷ Sign Up | LUC00079 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2334687 | ⤷ Sign Up | 2018C/027 | Belgium | ⤷ Sign Up |
| European Patent Office | 2334687 | ⤷ Sign Up | PA2018510 | Lithuania | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
